26333042|t|Valproic acid protects against haemorrhagic shock-induced signalling changes via PPARgamma activation in an in vitro model.
26333042|a|BACKGROUND AND PURPOSE: Valproic acid (VPA), a widely used epilepsy and bipolar disorder treatment, provides acute protection against haemorrhagic shock-induced mortality in a range of in vivo models through an unknown mechanism. In the liver, this effect occurs with a concomitant protection against a decrease in GSK3beta-Ser(9) phosphorylation. Here, we developed an in vitro model to investigate this protective effect of VPA and define a molecular mechanism. EXPERIMENTAL APPROACH: The human hepatocarcinoma cell line (Huh7) was exposed to conditions occurring during haemorrhagic shock (hypoxia, hypercapnia and hypothermia) to investigate the changes in GSK3beta-Ser(9) phosphorylation for a 4 h period following treatment with VPA, related congeners, PPAR agonists, antagonists and siRNA. KEY RESULTS: Huh7 cells undergoing combined hypoxia, hypercapnia, and hypothermia reproduced the reduced GSK3beta-Ser(9) phosphorylation shown in vivo during haemorrhagic shock, and this change was blocked by VPA. The protective effect occurred through upstream PTEN and Akt signalling, and prevented downstream beta-catenin degradation while increasing histone 2/3 acetylation. This effect was reproduced by several VPA-related compounds with known PPARgamma agonist activity, independent of histone deacetylase (HDAC) inhibitory activity. Specific pharmacological inhibition (by T0070907) or knockdown of PPARgamma blocked the protective effect of VPA against these signalling changes and apoptosis. In addition, specific activation of PPARgamma using ciglitazone reproduced the changes induced by VPA in haemorrhagic shock-like conditions. CONCLUSION AND IMPLICATIONS: Changes in GSK3beta-Ser(9) phosphorylation in in vivo haemorrhagic shock models can be modelled in vitro, and this has identified a role for PPARgamma activation in the protective role of VPA.
26333042	0	13	Valproic acid	Chemical	MESH:D014635
26333042	31	49	haemorrhagic shock	Disease	MESH:D012771
26333042	81	90	PPARgamma	Gene	5468
26333042	148	161	Valproic acid	Chemical	MESH:D014635
26333042	163	166	VPA	Chemical	MESH:D014635
26333042	183	191	epilepsy	Disease	MESH:D004827
26333042	196	212	bipolar disorder	Disease	MESH:D001714
26333042	258	276	haemorrhagic shock	Disease	MESH:D012771
26333042	439	447	GSK3beta	Gene	2932
26333042	448	454	Ser(9)	Chemical	-
26333042	550	553	VPA	Chemical	MESH:D014635
26333042	615	620	human	Species	9606
26333042	621	636	hepatocarcinoma	Disease	
26333042	648	652	Huh7	CellLine	CVCL:0336
26333042	697	715	haemorrhagic shock	Disease	MESH:D012771
26333042	717	724	hypoxia	Disease	MESH:D000860
26333042	726	737	hypercapnia	Disease	MESH:D006935
26333042	742	753	hypothermia	Disease	MESH:D007035
26333042	785	793	GSK3beta	Gene	2932
26333042	794	800	Ser(9)	Chemical	-
26333042	859	862	VPA	Chemical	MESH:D014635
26333042	934	938	Huh7	CellLine	CVCL:0336
26333042	965	972	hypoxia	Disease	MESH:D000860
26333042	974	985	hypercapnia	Disease	MESH:D006935
26333042	991	1002	hypothermia	Disease	MESH:D007035
26333042	1026	1034	GSK3beta	Gene	2932
26333042	1035	1041	Ser(9)	Chemical	-
26333042	1079	1097	haemorrhagic shock	Disease	MESH:D012771
26333042	1130	1133	VPA	Chemical	MESH:D014635
26333042	1183	1187	PTEN	Gene	5728
26333042	1192	1195	Akt	Gene	207
26333042	1233	1245	beta-catenin	Gene	1499
26333042	1338	1341	VPA	Chemical	MESH:D014635
26333042	1371	1380	PPARgamma	Gene	5468
26333042	1414	1433	histone deacetylase	Gene	9734
26333042	1435	1439	HDAC	Gene	9734
26333042	1502	1510	T0070907	Chemical	MESH:C458508
26333042	1528	1537	PPARgamma	Gene	5468
26333042	1571	1574	VPA	Chemical	MESH:D014635
26333042	1659	1668	PPARgamma	Gene	5468
26333042	1675	1686	ciglitazone	Chemical	MESH:C039671
26333042	1721	1724	VPA	Chemical	MESH:D014635
26333042	1728	1746	haemorrhagic shock	Disease	MESH:D012771
26333042	1804	1812	GSK3beta	Gene	2932
26333042	1813	1819	Ser(9)	Chemical	-
26333042	1847	1865	haemorrhagic shock	Disease	MESH:D012771
26333042	1934	1943	PPARgamma	Gene	5468
26333042	1981	1984	VPA	Chemical	MESH:D014635
26333042	Negative_Correlation	MESH:D014635	MESH:D004827
26333042	Negative_Correlation	MESH:D014635	2932
26333042	Negative_Correlation	MESH:C458508	MESH:D014635
26333042	Negative_Correlation	MESH:D014635	MESH:D000860
26333042	Negative_Correlation	MESH:D012771	2932
26333042	Positive_Correlation	2932	5468
26333042	Positive_Correlation	MESH:D014635	5468
26333042	Association	MESH:C039671	MESH:D012771
26333042	Negative_Correlation	MESH:D014635	1499
26333042	Negative_Correlation	MESH:D014635	MESH:D006935
26333042	Negative_Correlation	MESH:D000860	2932
26333042	Negative_Correlation	MESH:D014635	MESH:D007035
26333042	Negative_Correlation	MESH:D014635	MESH:D001714
26333042	Negative_Correlation	MESH:D014635	MESH:D012771
26333042	Positive_Correlation	MESH:C039671	5468
26333042	Negative_Correlation	MESH:D007035	2932
26333042	Association	MESH:D012771	5468
26333042	Negative_Correlation	MESH:D006935	2932

